Skip to main content
  • Register
  • Help
  • Contact us

Amyris Inc (AMRS) USD0.0001

Sell:$12.22 Buy:$12.30 Change: $0.81 (7.10%)
NASDAQ:0.88%
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$12.22
Buy:$12.30
Change: $0.81 (7.10%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:$12.22
Buy:$12.30
Change: $0.81 (7.10%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amyris, Inc. is an industrial biotechnology company. The Company is primarily focused on applying its technology platform to engineer, manufacture and sell high performance, natural, sustainably-sourced products into the Health & Wellness, Clean Beauty, and Flavor and Fragrance markets. Its technology platform enables users to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into volume, high-value ingredients. Its biotechnology platform and industrial fermentation process replace existing complex and expensive manufacturing processes. The Company’s platform is used to design, build, optimize and upscale strains producing eight distinct molecules at commercial volumes, to more than 15 commercial ingredients.

Contact details

Address:
5885 Hollis St Ste 100
EMERYVILLE
94608-2405
United States
Telephone:
+1 (510) 4500761
Website:
https://www.amyris.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AMRS
ISIN:
US03236M2008
Market cap:
$3.72 billion
Shares in issue:
273.27 million
Sector:
Specialty Chemicals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Geoffrey Duyk
    Independent Interim Chairman of the Board
  • John Melo
    President, Chief Executive Officer, Director
  • Han Kieftenbeld
    Chief Financial Officer
  • Eduardo Alvarez
    Chief Operating Officer
  • Sheila Pollak
    Chief Marketing Officer - Biossance
  • Nicole Kelsey
    General Counsel, Secretary
  • Francisco Costa
    Chief Creative Officer
  • Kathleen Valiasek
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.